James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center, Part of Hackensack University Medical Center, shares his impression of the Phase 3 ASCERTAIN study investigating cedazuridine and decitabine versus decitabine in myelodysplastic syndromes (MDS).
